Genprex Inc. (GNPX)
Symbol Info
Listed Symbol GNPX
Name Genprex Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-0.89
Price Info
21 Day Moving Average $0.9014
21 Day EMA $0.904540
50 Day Moving Average $0.9652
50 Day EMA $1.002670
200 Day EMA $1.675910
200 Day Moving Average 1.390910
52 Week High $2.56
52 Week Low $0.64
52 Week Change $-60.450000
Alpha -0.002791
Beta 1.0992
Standard Deviation 0.609112
R2 0.006582
Periods 18
Share Information
10 Day Average Volume 89,985
20 Day Average Volume 56,981
30 Day Average Volume 46,662
50 Day Average Volume 56,746
Outstanding Shares 15,842,855
Float Shares 15,224,094
Percent Float 96.09%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 18
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 28,273
Institute Holdings Percent 6.200000
Institute Sold Previous 3 Months 246,671
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 4.10%
Insider Sold Previous 3 Months -
Insiders Shares Owned 618,761
Price Change
7 Day Price Change $-0.0223
7 Day Percent Change -2.50%
21 Day Price Change $-0.0659
21 Day Percent Change -7.04%
30 Day Price Change $-0.0562
30 Day Percent Change -6.07%
Month To Date Price Change $-0.0099
Month To Date Percent -1.13%
90 Day Price Change $-0.5699
90 Day Percent Change -39.58%
Quarter To Date $-0.3699
Quarter To Date Percent -29.83%
180 Day Price Change $-0.7099
180 Day Percent Change -44.93%
200 Day Price Change $-0.5699
200 Day Percent Change -39.58%
Year To Date $-0.2299
Year To Date Percent -20.90%
Profile
Description Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
Details
Issue Type CS
Market Cap $13,784,868
Sec Type
Auditor Daszkal Bolton LLP
Total Shares Outstanding 15,842,855
CEO J. Rodney Varner
Employees 7
Last Audit UQ
Classification
CIK 0001595248
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1601 Trinity Street, Building B
Suite 3.322
Austin, TX 78712-1885
Website https://www.genprex.com
Facisimile
Telephone +1 877 744-4679
Email
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $10,237,313
Price To Sales -
Price To Free Cash -2.1
PE High Last 5 Years -
Price To Book 2.8
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 3.0
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 6.2
Leverage Ratio 1.1
Quick Ratio 4.8
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -119.77
Return On Equity -128.06
Return On Capital -128.55
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
GNPX
Genprex
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190915 10:11:27